MSME (Udyam registered) Ministry of MSME
- Udyam number
- UDYAM-TN-02-0005460
Market Cap
₹1,047 Cr
BAFNAPH · NSE
Share Price
₹451.60
+2.00% today
Revenue
₹42.47 Cr
FY 2019-20 · -2.7% YoY
EBITDA
−₹21.33 Cr
Margin -50.2%
Net Profit
−₹2.17 Cr
FY 2019-20 · +89.1% YoY
Debt / Equity
0.70
Interest cover -0.4x
Authorised capital
₹40 Cr
Registered with MCA
Paid-up capital
₹23.66 Cr
Issued & subscribed
About Bafna Pharmaceuticals Limited
Data last updated:
Bafna Pharmaceuticals Limited is a public limited company based in Chennai, Tamil Nadu, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 28 March 1995 and has been in existence for over 31 years.
The company is registered with the Registrar of Companies (ROC), Chennai, under CIN L24294TN1995PLC030698. Its GSTIN is 33AAACB3109Q1ZR (Tamil Nadu). The company holds 6 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 532989 and NSE: BAFNAPH.
The company has an authorised share capital of ₹40 Cr and a paid-up capital of ₹23.66 Cr. It is led by directors including Shanmugam Hemalatha (Whole-Time Director) and Vinayak Dinesh Dendukuri (Whole-Time Director).
Its last annual general meeting (AGM) was held on 19 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 299 Thambu Chetty Streetmadras 600 001 Madras 600 001, Chennai, Tamil Nadu, India – 600001.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹150.62 Cr, a growth of 3.3% compared to the previous year. For the same year it recorded a net profit of ₹11.1 Cr (net margin 7.4%) and EBITDA of ₹15.94 Cr (EBITDA margin 10.6%). The net worth stands at ₹96.15 Cr (up 13.4% YoY). Total assets are valued at ₹137.99 Cr (up 19.6% YoY).
The company has about 381 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Bafna Pharma. As per MCA filings, the company has open charges of ₹74 Cr and satisfied charges of ₹169.66 Cr on record. Court records list 122 cases involving the company, including 79 filed by the company and 43 filed against it; 18 cases are pending. The company has 65 deals on record (49 market trades, 9 secondary share transfers, 6 funding rounds), with disclosed funding of ₹14.58 Cr; the latest was in August 2026. Its 5 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 1 larger and 4 smaller; the largest is Leben Laboratories Private Limited with revenue of ₹149.37 Cr. The company has 10 MSME Form 1 returns on record between 2020 and 2023, listing 758 overdue payments to 346 micro and small suppliers.
Bafna Pharmaceuticals Limited is registered as an MSME under the Udyam registration framework (Reg. No. UDYAM-TN-02-0005460). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website bafnapharma.com.
Company details
CIN L24294TN1995PLC030698
Registration Number 030698
Incorporation Date 28 March 1995
ROC Chennai
Listing Status Listed - Listed on NSE (BAFNAPH); Listed on BSE (532989)
Company Status Active
Date of Last AGM 19 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification MSME
Udyam Registration UDYAM-TN-02-0005460
CIN history
Bafna Pharmaceuticals has one previous CIN (Corporate Identification Number): U24294TN1995PLC030698. The current CIN is L24294TN1995PLC030698, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24294TN1995PLC030698 | Current |
| U24294TN1995PLC030698 | Previous |
Key People
Shanmugam Hemalatha Whole-Time Director Vinayak Dinesh Dendukuri Whole-Time Director Palamadai Krishnan Sundaresan Director Recognitions & Rankings of Bafna Pharmaceuticals
Contact details
Bafna Pharmaceuticals Limited's registered office is in Madras 600 001, Tamil Nadu. Its website is bafnapharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address299 Thambu Chetty Streetmadras 600 001 Madras 600 001, Chennai, Tamil Nadu, India – 600001
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Bafna Pharmaceuticals Limited, buy the company report.
Comprehensive company report
Bafna Pharmaceuticals Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Bafna Pharmaceuticals operates one associated brand: Bafna Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Provider of formulation services for pharmaceutical industry | bafnapharma.com |
Business activity
The main business activity of Bafna Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Bafna Pharmaceuticals Limited, buy the company report.
Financials of Bafna Pharmaceuticals Limited
FY 2025-26 filings availableBafna Pharmaceuticals Limited reported revenue of ₹150.62 Cr (up 3.3% YoY) for FY 2025-26.
Financial Highlights
FY 2019-20 · ConsolidatedRevenue
₹42.47 Cr
-2.7% YoY
EBITDA
−₹21.33 Cr
-63.2% YoY
Profit After Tax
−₹2.17 Cr
+89.1% YoY
Net Worth
₹51.12 Cr
+168.2% YoY
Total Assets
₹54.21 Cr
-17.5% YoY
Total Debt
₹3.02 Cr
-93.5% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 | FY 2013-14 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 42.47 | 43.63 | 47.17 | 64.96 | 85.32 | 97.67 | 185 |
| Revenue growth | -2.7% | -7.5% | -27.4% | -23.9% | -12.6% | -47.3% | - |
| EBITDA | (21.33) | (13.07) | (35.12) | (5.82) | 0.51 | (20.51) | 22.83 |
| EBITDA margin | -50.2% | -30.0% | -74.5% | -9.0% | +0.6% | -21.0% | +12.3% |
| Profit before tax | (24.44) | (17.28) | (14.70) | (20.37) | (15.33) | 6.05 | 2.48 |
| Net profit | (2.17) | (19.88) | (44.56) | (19.10) | (14.04) | (29.86) | 1.39 |
| Net profit margin | -5.1% | -45.6% | -94.5% | -29.4% | -16.5% | -30.6% | +0.8% |
| EPS (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.31 | 0.75 |
| Balance sheet | |||||||
| Total assets | 54.21 | 65.71 | 96.70 | 137 | 139 | 142 | 179 |
| Net worth | 51.12 | 19.06 | 37.93 | 42.67 | 57.76 | 71.78 | 68.86 |
| Total debt | 3.02 | 46.23 | 46.54 | 82.38 | 80.48 | 68.65 | 108 |
| Cash & bank | 8.48 | 2.71 | 2.95 | 2.66 | 2.71 | 2.77 | 2.81 |
| Net working capital | 18.99 | 0.88 | 12.17 | 39.09 | 72.73 | 73.02 | 106 |
| Cash flow | |||||||
| Cash from operations | (34.31) | (1.79) | (7.05) | (0.95) | 0.91 | 10.66 | 1.61 |
| Cash from investing | 32.77 | 15.36 | 37.97 | (5.42) | (0.36) | 60.13 | (6.71) |
| Cash from financing | 7.30 | (13.81) | (30.63) | 6.31 | (0.61) | (70.83) | (13.16) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 151 | 146 | 152 | 115 | 85.14 | 71.22 | 42.47 |
| Revenue growth | +3.3% | -4.3% | +32.2% | +35.5% | +19.6% | +67.7% | - |
| EBITDA | 15.94 | 9.03 | 11.11 | 15.70 | 9.80 | 10.30 | (22.10) |
| EBITDA margin | +10.6% | +6.2% | +7.3% | +13.6% | +11.5% | +14.5% | -52.0% |
| Profit before tax | 10.97 | 4.15 | 7.34 | 11.60 | 5.22 | 5.83 | (25.21) |
| Net profit | 11.10 | 6.37 | 7.27 | 11.12 | 7.38 | 5.83 | (1.88) |
| Net profit margin | +7.4% | +4.4% | +4.8% | +9.6% | +8.7% | +8.2% | -4.4% |
| EPS (₹) | 4.69 | 1.76 | 3.11 | 4.79 | 2.21 | 2.46 | (106.54) |
| Balance sheet | |||||||
| Total assets | 138 | 115 | 107 | 97.60 | 73.87 | 72.16 | 53.96 |
| Net worth | 96.15 | 84.81 | 80.84 | 73.46 | 61.97 | 56.77 | 50.95 |
| Total debt | 37.43 | 28.20 | 24.39 | 22.93 | 11.06 | 15.29 | 3.02 |
| Cash & bank | 2.02 | 3.43 | 1.40 | 7.81 | 0.17 | 1.80 | 8.48 |
| Net working capital | 52.12 | 47.05 | 53.33 | 55.32 | 34.61 | 35.35 | 18.77 |
| Cash flow | |||||||
| Cash from operations | 15.37 | 22.14 | 9.48 | 4.95 | 9.73 | (13.61) | (34.27) |
| Cash from investing | (22.40) | (21.16) | (15.05) | (7.49) | (6.54) | (5.35) | 32.78 |
| Cash from financing | 5.62 | 1.06 | (0.85) | 10.18 | (4.81) | 12.28 | 7.27 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.58 | 42.24 | 38.29 | 35.47 | 34.62 | 39.06 | 33.19 | 40.32 |
| Revenue growth (YoY) | -23.2% | +8.1% | +15.4% | -12.0% | +4.0% | - | - | - |
| Other income | 1.91 | 1.76 | 1.22 | 1.18 | 0.60 | 1.03 | 0.19 | 1.02 |
| Total expenses | 25.70 | 38.69 | 35.24 | 31.19 | 29.56 | 37.74 | 30.14 | 36.53 |
| EBITDA | 0.88 | 3.55 | 3.05 | 4.28 | 5.06 | 1.32 | 3.05 | 3.79 |
| EBITDA margin | +3.3% | +8.4% | +8.0% | +12.1% | +14.6% | +3.4% | +9.2% | +9.4% |
| Depreciation | 1.78 | 1.66 | 1.57 | 1.47 | 1.37 | 0.22 | 1.66 | 1.58 |
| Interest | 0.94 | 1.03 | 0.86 | 0.86 | 0.91 | 0.82 | 0.64 | 0.62 |
| Profit before tax | 0.07 | 2.62 | 1.84 | 3.13 | 3.38 | 1.31 | 0.94 | 2.61 |
| Tax | 0.00 | (0.13) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 28 Oct 2026
| Particulars | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 | FY 2013-14 |
|---|---|---|---|---|---|---|---|
| Revenue | 42.47 | 43.63 | 47.17 | 64.96 | 85.32 | 97.67 | 185 |
| Revenue growth | -2.7% | -7.5% | -27.4% | -23.9% | -12.6% | -47.3% | - |
| Other income | 0.26 | 1.40 | 31.33 | 1.14 | 1.98 | 46.01 | 1.85 |
| Total expenses | 63.80 | 56.70 | 82.29 | 70.78 | 84.81 | 118 | 162 |
| Employee cost | 10.25 | 9.01 | 7.47 | 6.81 | 6.99 | 10.78 | 14.24 |
| EBITDA | (21.33) | (13.07) | (35.12) | (5.82) | 0.51 | (20.51) | 22.83 |
| EBITDA margin | -50.2% | -30.0% | -74.5% | -9.0% | +0.6% | -21.0% | +12.3% |
| Depreciation | 3.27 | 3.48 | 3.97 | 4.22 | 4.86 | 5.99 | 8.99 |
| Interest | 0.10 | 2.13 | 6.94 | 11.47 | 12.96 | 13.46 | 13.21 |
| Profit before tax | (24.44) | (17.28) | (14.70) | (20.37) | (15.33) | 6.05 | 2.48 |
| Tax | 0.00 | 1.07 | 2.19 | (0.90) | (0.18) | (0.15) | 1.05 |
| Net profit | (2.17) | (19.88) | (44.56) | (19.10) | (14.04) | (29.86) | 1.39 |
| Net profit margin | -5.1% | -45.6% | -94.5% | -29.4% | -16.5% | -30.6% | +0.8% |
| EPS (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.31 | 0.75 |
| Particulars | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 | FY 2013-14 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 2.37 | 23.66 | 23.66 | 18.66 | 18.66 | 18.66 | 18.66 |
| Reserves & surplus | (6.61) | (4.60) | 14.27 | 20.01 | 39.10 | 53.12 | 50.20 |
| Shareholders' funds (net worth) | 51.12 | 19.06 | 37.93 | 42.67 | 57.76 | 71.78 | 68.86 |
| Minority interest | 0.08 | (0.21) | (0.73) | (0.55) | 0.00 | 0.93 | 0.89 |
| Secured loans | 0.00 | 44.10 | 44.37 | 80.14 | 80.48 | 68.65 | 108 |
| Unsecured loans | 3.02 | 2.13 | 2.17 | 2.24 | 0.00 | 0.00 | 0.00 |
| Total debt | 3.02 | 46.23 | 46.54 | 82.38 | 80.48 | 68.65 | 108 |
| Total liabilities | 54.21 | 65.71 | 96.70 | 137 | 139 | 142 | 179 |
| Assets | |||||||
| Gross block | 74.13 | 72.91 | 79.77 | 79.65 | 79.67 | 77.36 | 90.61 |
| Net block | 35.01 | 37.05 | 44.89 | 48.61 | 52.61 | 54.56 | 69.28 |
| Capital work in progress | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 16.90 | 16.90 | 16.90 | 0.00 |
| Inventories | 11.41 | 9.28 | 10.67 | 16.74 | 16.38 | 16.12 | 27.40 |
| Sundry debtors | 6.03 | 24.83 | 24.28 | 53.78 | 67.96 | 88.69 | 97.51 |
| Cash & bank balances | 8.48 | 2.71 | 2.95 | 2.66 | 2.71 | 2.77 | 2.81 |
| Loans & advances | 10.17 | 11.64 | 10.83 | 4.01 | 35.42 | 19.51 | 28.76 |
| Total current assets | 36.09 | 48.46 | 48.73 | 77.19 | 122 | 127 | 156 |
| Total current liabilities | 17.10 | 47.58 | 36.56 | 38.10 | 49.74 | 54.07 | 50.16 |
| Net working capital | 18.99 | 0.88 | 12.17 | 39.09 | 72.73 | 73.02 | 106 |
| Total assets | 54.21 | 65.71 | 96.70 | 137 | 139 | 142 | 179 |
| Particulars | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 | FY 2013-14 |
|---|---|---|---|---|---|---|---|
| Opening cash | 2.71 | 2.95 | 2.66 | 2.71 | 2.77 | 2.81 | 21.07 |
| Net cash from operating activities | (34.31) | (1.79) | (7.05) | (0.95) | 0.91 | 10.66 | 1.61 |
| Net cash from investing activities | 32.77 | 15.36 | 37.97 | (5.42) | (0.36) | 60.13 | (6.71) |
| Net cash from financing activities | 7.30 | (13.81) | (30.63) | 6.31 | (0.61) | (70.83) | (13.16) |
| Net change in cash | 5.77 | (0.24) | 0.29 | (0.06) | (0.06) | (0.04) | (18.26) |
| Closing cash | 8.48 | 2.71 | 2.95 | 2.66 | 2.71 | 2.77 | 2.81 |
| Particulars | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 | FY 2013-14 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -2.7% | -7.5% | -27.4% | -23.9% | -12.6% | -47.3% | - |
| EBITDA growth | -63.2% | +62.8% | -503.4% | -1241.2% | +102.5% | -189.8% | - |
| PBT growth | -41.4% | -17.6% | +27.8% | -32.9% | - | +144.0% | -54.9% |
| Net income growth | +89.1% | +55.4% | -133.3% | -36.0% | +53.0% | -2248.2% | - |
| Revenue CAGR (3Y) | -13.2% | -20.0% | -21.5% | -29.5% | -21.4% | - | - |
| EBITDA CAGR (3Y) | +54.2% | - | +19.6% | - | -71.7% | - | - |
| Profitability & leverage | |||||||
| Net income margin | -57.6% | -42.1% | -35.8% | -30.0% | -17.8% | +6.4% | +0.8% |
| Return on capital employed | 0.0% | 0.0% | 0.0% | 0.0% | -1.7% | -11.8% | +9.0% |
| Return on net worth | 0.0% | 0.0% | 0.0% | 0.0% | -23.4% | -42.4% | +2.1% |
| Debt / equity | 0.70 | 1.63 | 1.60 | 1.62 | 1.15 | 1.26 | 1.53 |
| Long-term debt / equity | 0.34 | 0.41 | 0.05 | 0.37 | 0.36 | 0.25 | 0.35 |
| Interest cover | -0.41 | -12.87 | -17.75 | -114.24 | -297.93 | -50.79 | 95.45 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.58 | 0.57 | 0.59 | 0.82 | 1.10 | 1.17 | 2.10 |
| Inventory turnover | 4.11 | 4.37 | 3.44 | 3.92 | 5.32 | 4.53 | 7.48 |
| Debtors turnover | 2.75 | 1.78 | 1.21 | 1.07 | 1.10 | 1.06 | 1.96 |
| EPS (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.31 | 0.75 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | (17.93) | 8.06 | 16.03 | 20.73 | 30.96 | 38.47 | 36.91 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.58 | 42.24 | 38.29 | 35.47 | 34.62 | 39.06 | 33.19 | 40.32 |
| Revenue growth (YoY) | -23.2% | +8.1% | +15.4% | -12.0% | +4.0% | - | - | - |
| Other income | 1.91 | 1.76 | 1.22 | 1.18 | 0.60 | 1.03 | 0.19 | 1.02 |
| Total expenses | 25.70 | 38.69 | 35.24 | 31.19 | 29.56 | 37.74 | 30.14 | 36.53 |
| EBITDA | 0.88 | 3.55 | 3.05 | 4.28 | 5.06 | 1.32 | 3.05 | 3.79 |
| EBITDA margin | +3.3% | +8.4% | +8.0% | +12.1% | +14.6% | +3.4% | +9.2% | +9.4% |
| Depreciation | 1.78 | 1.66 | 1.57 | 1.47 | 1.37 | 0.22 | 1.66 | 1.58 |
| Interest | 0.94 | 1.03 | 0.86 | 0.86 | 0.91 | 0.82 | 0.64 | 0.62 |
| Profit before tax | 0.07 | 2.62 | 1.84 | 3.13 | 3.38 | 1.31 | 0.94 | 2.61 |
| Tax | 0.00 | (0.13) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 151 | 146 | 152 | 115 | 85.14 | 71.22 | 42.47 |
| Revenue growth | +3.3% | -4.3% | +32.2% | +35.5% | +19.6% | +67.7% | - |
| Other income | 4.76 | 2.74 | 3.52 | 3.27 | 1.70 | 0.75 | 0.26 |
| Total expenses | 135 | 137 | 141 | 99.65 | 75.34 | 60.92 | 64.57 |
| Employee cost | 21.92 | 21.03 | 19.03 | 15.87 | 14.65 | 11.98 | 10.25 |
| EBITDA | 15.94 | 9.03 | 11.11 | 15.70 | 9.80 | 10.30 | (22.10) |
| EBITDA margin | +10.6% | +6.2% | +7.3% | +13.6% | +11.5% | +14.5% | -52.0% |
| Depreciation | 6.07 | 4.89 | 5.00 | 5.33 | 5.49 | 4.48 | 3.27 |
| Interest | 3.66 | 2.73 | 2.29 | 2.04 | 0.79 | 0.74 | 0.10 |
| Profit before tax | 10.97 | 4.15 | 7.34 | 11.60 | 5.22 | 5.83 | (25.21) |
| Tax | (0.13) | 0.00 | 0.00 | 0.28 | 0.00 | 0.00 | 0.00 |
| Net profit | 11.10 | 6.37 | 7.27 | 11.12 | 7.38 | 5.83 | (1.88) |
| Net profit margin | +7.4% | +4.4% | +4.8% | +9.6% | +8.7% | +8.2% | -4.4% |
| EPS (₹) | 4.69 | 1.76 | 3.11 | 4.79 | 2.21 | 2.46 | (106.54) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 23.66 | 23.66 | 23.66 | 23.66 | 23.66 | 23.66 | 2.37 |
| Reserves & surplus | 72.49 | 61.15 | 57.18 | 49.80 | 38.31 | 33.11 | (6.78) |
| Shareholders' funds (net worth) | 96.15 | 84.81 | 80.84 | 73.46 | 61.97 | 56.77 | 50.95 |
| Secured loans | 35.63 | 26.70 | 22.89 | 21.42 | 9.04 | 2.50 | 0.00 |
| Unsecured loans | 1.80 | 1.50 | 1.50 | 1.51 | 2.02 | 12.79 | 3.02 |
| Total debt | 37.43 | 28.20 | 24.39 | 22.93 | 11.06 | 15.29 | 3.02 |
| Total liabilities | 138 | 115 | 107 | 97.60 | 73.87 | 72.16 | 53.96 |
| Assets | |||||||
| Gross block | 134 | 106 | 99.49 | 94.66 | 87.94 | 79.57 | 74.09 |
| Net block | 81.79 | 58.78 | 40.21 | 40.23 | 38.85 | 35.97 | 34.97 |
| Capital work in progress | 3.13 | 7.31 | 12.27 | 1.50 | 0.00 | 0.83 | 0.21 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 28.90 | 28.09 | 29.64 | 22.22 | 20.28 | 15.44 | 11.41 |
| Sundry debtors | 43.93 | 40.17 | 45.39 | 41.15 | 14.78 | 9.56 | 6.03 |
| Cash & bank balances | 2.02 | 3.43 | 1.40 | 7.81 | 0.17 | 1.80 | 8.48 |
| Loans & advances | 14.80 | 13.04 | 17.34 | 16.13 | 15.65 | 22.86 | 9.95 |
| Total current assets | 89.65 | 84.73 | 93.77 | 87.31 | 50.88 | 49.66 | 35.87 |
| Total current liabilities | 37.53 | 37.68 | 40.44 | 31.99 | 16.27 | 14.31 | 17.10 |
| Net working capital | 52.12 | 47.05 | 53.33 | 55.32 | 34.61 | 35.35 | 18.77 |
| Total assets | 138 | 115 | 107 | 97.60 | 73.87 | 72.16 | 53.96 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 3.43 | 1.40 | 7.81 | 0.17 | 1.80 | 8.48 | 2.70 |
| Net cash from operating activities | 15.37 | 22.14 | 9.48 | 4.95 | 9.73 | (13.61) | (34.27) |
| Net cash from investing activities | (22.40) | (21.16) | (15.05) | (7.49) | (6.54) | (5.35) | 32.78 |
| Net cash from financing activities | 5.62 | 1.06 | (0.85) | 10.18 | (4.81) | 12.28 | 7.27 |
| Net change in cash | (1.41) | 2.04 | (6.41) | 7.64 | (1.63) | (6.68) | 5.78 |
| Closing cash | 2.02 | 3.43 | 1.40 | 7.81 | 0.17 | 1.80 | 8.48 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +3.3% | -4.3% | +32.2% | +35.5% | +19.6% | +67.7% | - |
| EBITDA growth | +76.5% | -18.7% | -29.2% | +60.2% | -4.9% | +146.6% | - |
| PBT growth | +164.3% | -43.5% | -36.7% | +122.2% | -10.5% | +9998.0% | -38.3% |
| Net income growth | +74.3% | -12.4% | -34.6% | +50.7% | +26.6% | +410.1% | - |
| Revenue CAGR (3Y) | +9.3% | +19.7% | +28.9% | +39.5% | +25.0% | +14.7% | -13.2% |
| EBITDA CAGR (3Y) | +0.5% | -2.7% | +2.6% | - | - | - | +61.9% |
| Profitability & leverage | |||||||
| Net income margin | +7.4% | +2.9% | +4.8% | +9.8% | +6.1% | +8.2% | -59.4% |
| Return on capital employed | +8.9% | +5.8% | +6.3% | +9.4% | +5.8% | +6.7% | 0.0% |
| Return on net worth | +8.7% | +5.0% | +5.7% | +8.9% | +5.8% | +6.5% | 0.0% |
| Debt / equity | 0.36 | 0.32 | 0.31 | 0.25 | 0.22 | 0.17 | 0.69 |
| Long-term debt / equity | 0.18 | 0.15 | 0.12 | 0.10 | 0.09 | 0.08 | 0.33 |
| Interest cover | 37.08 | 65.94 | 37.48 | 19.67 | 18.33 | 12.71 | -0.39 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.26 | 1.42 | 1.57 | 1.26 | 1.02 | 0.93 | 0.58 |
| Inventory turnover | 5.29 | 5.05 | 5.88 | 5.43 | 4.77 | 5.31 | 4.11 |
| Debtors turnover | 3.58 | 3.41 | 3.52 | 4.12 | 7.00 | 9.14 | 2.75 |
| EPS (₹) | 4.69 | 1.76 | 3.11 | 4.79 | 2.21 | 2.46 | (106.54) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 40.64 | 35.85 | 34.17 | 31.05 | 26.19 | 24.00 | (18.64) |
To see the full year-wise statements and ratios of Bafna Pharmaceuticals Limited, buy the company report.
Board of directors of Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals has 6 current directors and 22 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Palamadai Krishnan Sundaresan | Director | 19 Sep 2025 | 1 Years 1 Months | Current |
| Ravichandran Chitra Also directs: Basilic Fly Studio Limited, Proviniti India Private Limited, Rexa Insurance Broking Services Private Limited and 4 more | Director | 12 Nov 2020 | 5 Years 11 Months | Current |
| Shanmugam Hemalatha | Whole-Time Director | 10 Sep 2020 | 6 Years 1 Months | Current |
| Akila Chintalapati Raju | Director | 10 Sep 2020 | 6 Years 1 Months | Current |
| Vinayak Dinesh Dendukuri | Whole-Time Director | 26 Jun 2023 | 3 Years 4 Months | Current |
| Upendar Mekala Reddy | Director | 26 Jun 2023 | 3 Years 4 Months | Current |
Peer comparison
Bafna Pharmaceuticals Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Bafna Pharmaceuticals Limitedthis company | ₹150.62 Cr (FY 2026) | ₹11.1 Cr | 7.4% | 3.3% | 381 | Chennai, Tamil Nadu, India |
| Leben Laboratories Private Limited | ₹149.37 Cr (FY 2025) | 15.0% | Akola, Maharashtra, India | |||
| Celon Laboratories Private Limited | ₹148.17 Cr (FY 2025) | -7.0% | Hyderabad, Telangana, India | |||
| Sionc Pharmaceuticals Private Limited | ₹147.51 Cr (FY 2024) | 13.0% | Visakhapatnam, Andhra Pradesh, India | |||
| Canton Laboratories Private Limited | ₹147.08 Cr (FY 2025) | 26.0% | Vadodara, Gujarat, India | |||
| Murli Krishna Pharma Private Limited | ₹146.68 Cr (FY 2025) | -21.0% | Pune, Maharashtra, India |
To see the full peer comparison of Bafna Pharmaceuticals Limited, buy the company report.
Auditor
Bafna Pharmaceuticals Limited is audited by Brahmayaa & CO for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Brahmayaa & CO | FY 2024 | 000511S |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 75.00%, foreign institutional investors hold 9.30%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 15.70%.
Sep 2026
QUARTER
75.00% Promoters
9.30% FII (Foreign Institutional)
15.70% Retail & Others
Promoter holding - history
Now 75.00% · Sep 2026High 75.00% · Dec 2025Low 75.00% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% |
| Public | 25.00% | 25.00% | 25.00% | 25.00% |
Charges & borrowings
Open charges
₹74 Cr
Satisfied charges
₹169.66 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 27 Jul 2026 | 101350397 | Others | ₹3.75 Cr | Open | |
| 27 Jul 2026 | 101350403 | Others | ₹1.4 Cr | Open | |
| 13 Jun 2025 | 101111395 | Others | ₹11.5 Cr | Open | |
| 11 Sep 2024 | 100983429 | Others | ₹6.35 Cr | Open | |
| 21 Feb 2024 | 100870424 | Others | ₹12 Cr | Open |
To see the full charge records of Bafna Pharmaceuticals Limited, buy the company report.
Total charge records: 21 View all charges
Deals & funding
Bafna Pharmaceuticals Limited has 65 deals on record (49 market trades, 9 secondary share transfers, 6 funding rounds), with disclosed funding of ₹14.58 Cr; the latest was in August 2026.
Total deals
65
Market trades
49
Secondary share transfers
9
Funding rounds
6
IPO
1
Disclosed funding
₹14.58 Cr
Deals on record (5 of 65)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2017 | Secondary share transfer | Undisclosed | Buyer: Ipo Shareholders- Bafna Pharmaceuticals Limited, Krypton Investment Consultancy Private Limited , 2 individuals Seller: 3 individuals |
| Sep 2016 | Secondary share transfer | Undisclosed | Buyer: Ipo Shareholders- Bafna Pharmaceuticals Limited, 3 individuals Seller: 4 individuals |
| Sep 2015 | Secondary share transfer | Undisclosed | Buyer: Ipo Shareholders- Bafna Pharmaceuticals Limited, 3 individuals Seller: Nirmal Bang Financial Services Private Limited , Monarch Networth Capital Limited , Bull Investments Madras Private Limited , an individual |
| Sep 2014 | Secondary share transfer | Undisclosed | Buyer: Ifin Securities Finance Limited , Ipo Shareholders- Bafna Pharmaceuticals Limited, Sammaan Finserve Limited , an individual Seller: Indiabulls Housing Finance ltd, Indiabulls Securities Ltd -Client Margin Account, Nirmal Bang Financial Services Private Limited , an individual |
| Sep 2013 | Secondary share transfer | Undisclosed | Buyer: Nirmal Bang Financial Services Private Limited , Indiabulls Securities Ltd -Client Margin Account, 2 individuals Seller: 4 individuals |
To see the full deal history of Bafna Pharmaceuticals Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Bafna Pharmaceuticals Limited has 122 court cases on record: 79 filed by Bafna Pharmaceuticals, 43 filed against it. 18 cases are pending and 104 are disposed.
Total cases
122
Filed by the company
79
Filed against the company
43
Pending
18
Disposed
104
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 71 | 15 | 15 |
| District courts | 50 | 27 | 3 |
| Supreme Court | 1 | 1 | 0 |
Cases on record (5 of 122)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Madras High Court | Appeal | Filed by the company against Goldleaf Enterprise Pvt. Ltd. | Disposed |
| Supreme Court | Court case (1006-Company Law, Mrtp, Trai, Sebi, Idrai & Rbi : Others) | Filed against the company by Saravana Global Holdings Limited Manager No. 15, New Giri Road, Opp. Accord Hotel Off G.N. Chetty Road, T. Nagar , District: Chennai ,Chennai , Tamil Nadu and 1 other | Disposed |
| District court, Jodhpur Metro, Rajasthan | Civil suit | Filed against the company by Daga Poly Laminators Pvt Ltd | Disposed |
| District court, BENGALURU, Karnataka | Criminal complaint | Filed against the company by M/S Yuno Packaging Pvt Ltd | Disposed |
| District court, BENGALURU, Karnataka | Criminal complaint | Filed against the company by M/S Yuno Packaging Pvt Ltd | Disposed |
To see the full case history of Bafna Pharmaceuticals Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Bafna Pharmaceuticals Limited has 10 MSME Form 1 returns on record between 2020 and 2023, listing 758 overdue payments to 346 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 346)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Spansules Formulations India Private Limited | |||
| Letra Graphix Private Limited | |||
| an individual supplier | |||
| Siddhi Specialities | |||
| Unity Flexi Pack Global Private Limited |
To see the full MSME payment records of Bafna Pharmaceuticals Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Bafna Pharmaceuticals Limited has a workforce of 381 employees on its EPFO records as of Mar 31, 2025, across 1 active EPFO establishment.
Employee count
381
Active EPFO establishments
1
Employee growth
7.32%
GST
Bafna Pharmaceuticals has 6 GST registrations: 1 active and 5 cancelled or inactive.
Total GSTINs
6
Active
1
Cancelled / inactive
5
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 33AAACB3109Q1ZR | Tamil Nadu | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Bafna Pharmaceuticals Limited, buy the company report.
Recent activity
Bafna Pharmaceuticals Limited has 37 board changes on record since 1995: 22 appointments and 15 cessations. The latest: Palamadai Krishnan Sundaresan was appointed as Director on 19 Sep 2025.
Charges
A charge with Others amounted to Rs. 3.75 Cr with Charge ID 101350397 was registered on 27 Jul 2026.
Charges
A charge with Others amounted to Rs. 1.40 Cr with Charge ID 101350403 was registered on 27 Jul 2026.
Filing
Bafna Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Chennai.
AGM
Bafna Pharmaceuticals Limited last Annual general meeting of members was held on 19 Sep 2025 as per latest MCA records.
Appointed
Palamadai Krishnan Sundaresan was appointed as Director.
Charges
A charge registered on 23 May 2025 via Charge ID 101124057 with Others was fully satisfied on 04 Sep 2025.
Charges
A charge with Others amounted to Rs. 11.50 Cr with Charge ID 101111395 was registered on 13 Jun 2025.
Charges
A charge with Others of Rs. 20.00 Cr registered on 27 Oct 2021 with Charge ID 100502255 was modified on 13 Jun 2025.
Charges
A charge with Others amounted to Rs. 10.00 Cr with Charge ID 101124057 was registered on 23 May 2025.
Ceased
Krishna Yeachuri ceased to be Director.
Charges
A charge with Others of Rs. 6.35 Cr registered on 11 Sep 2024 with Charge ID 100983429 was modified on 03 Oct 2024.
Charges
A charge with Others amounted to Rs. 6.35 Cr with Charge ID 100983429 was registered on 11 Sep 2024.
73 earlier events are in the company report.
News
Frequently asked questions
Bafna Pharmaceuticals is an active public limited company based in Chennai, Tamil Nadu, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 28 March 1995 (31+ years old) and is registered under CIN L24294TN1995PLC030698. Listed on BSE: 532989 and NSE: BAFNAPH.
Bafna Pharmaceuticals reported revenue of ₹150.62 Cr for FY 2025-26 (up 3.3% YoY) based on standalone financials.
Bafna Pharmaceuticals has 6 current directors:
- Shanmugam Hemalatha - Whole-Time Director
- Vinayak Dinesh Dendukuri - Whole-Time Director
- Palamadai Krishnan Sundaresan - Director
- Ravichandran Chitra - Director
- Akila Chintalapati Raju - Director
- Upendar Mekala Reddy - Director
The latest financial statements of Bafna Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 19 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Bafna Pharmaceuticals is 33AAACB3109Q1ZR, registered in Tamil Nadu. The company has 6 GST registrations in all, of which 1 is active and 5 are cancelled or inactive.
The CIN (Corporate Identification Number) of Bafna Pharmaceuticals is L24294TN1995PLC030698. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Bafna Pharmaceuticals is a listed company as per MCA records. Its shares are listed on both BSE (code: 532989) and NSE (symbol: BAFNAPH).
Bafna Pharmaceuticals has 122 court cases on record: 79 filed by the company and 43 filed against it. 18 are pending. Most are in the high courts.
Bafna Pharmaceuticals was incorporated on 28 March 1995, making it 31+ years old. It is registered with the Registrar of Companies, Chennai.
Bafna Pharmaceuticals has 65 deals on record (49 market trades, 9 secondary share transfers, 6 funding rounds), with disclosed funding of ₹14.58 Cr; the latest was in August 2026.
The peers of Bafna Pharmaceuticals by revenue are Leben Laboratories Private Limited, Celon Laboratories Private Limited, Sionc Pharmaceuticals Private Limited, Canton Laboratories Private Limited, Murli Krishna Pharma Private Limited, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Palamadai Krishnan Sundaresan was appointed as Director on 19 Sep 2025. Krishna Yeachuri ceased to be Director on 31 Mar 2025. Babulal Kamlesh Kumar ceased to be Director on 09 Sep 2023. Bafna Pharmaceuticals has 37 board changes on record in total.